BioCentury
ARTICLE | Clinical News

Boehringer's nintedanib improves PFS in NSCLC Phase III

June 4, 2013 2:56 AM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) said second-line treatment with twice-daily nintedanib plus docetaxel met the primary endpoint of improving median progression-free survival (PFS) vs. placebo plus docetaxel in the Phase III LUME-Lung 1 trial to treat advanced non-small cell lung cancer (NSCLC) (3.4 vs. 2.7 months, p=0.0019). Nintedanib plus docetaxel missed the secondary endpoint of improving median overall survival (OS) vs. placebo plus docetaxel (10.1 vs. 9.1 months, p=0.272). Boehringer could not be reached for next steps. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...